[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-356285-en":3,"detail-sidebar-cat-0-en-105":50,"doc-seo-356285-105":98},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":11,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":27,"seo_description":14,"update_tm":28,"read_time":29,"preview_page_count":30,"preview_urls":31},356285,34359740700684,"Finn","https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487",8,"Research & Report","Efficacy and Safety of Different Neoadjuvant Treatment Regimens in Locally Advanced Squamous Head and Neck Cancer","Background: Head and neck squamous cell carcinoma (HNSCC) is a major global health burden, and about 60% of patients present with locally advanced disease (LA-HNSCC) despite generally favorable early-stage outcomes. Induction chemotherapy such as TPF can reduce tumor burden but is constrained by substantial toxicity, and no global consensus exists on the best neoadjuvant strategy. Aim: Compare efficacy and safety of different neoadjuvant options for LA-HNSCC. Methods and results: A network meta-analysis across major databases through Aug 2024 evaluated ORR, OS, PFS, and SAEs in 23 studies (4052 patients). Hyperthermia plus chemotherapy showed the best ORR and OS, immunotherapy plus chemotherapy led in PFS, while safety favored T and TP over hyperthermia plus chemotherapy. Conclusion: Hyperthermia plus chemotherapy and immunotherapy plus chemotherapy are promising, but safety requires further evaluation.","Cancer Reports  \nSYSTEMATIC REVIEW  OPEN ACCESS   \nEfficacy and Safety of Different Neoadjuvant Treatment Regimens in Locally Advanced Squamous Head and Neck Cancer  \nYa-ting Ding1,2  | Bin-bin Fang3 | Lian-bing Zhu2 | Ke-jin Qiu2 | Li-li Yang4 | Hui Ye4 | Yun-xia Lv5 | Geng-ming Cai1,4   \n1School of Clinical Medicine, Fujian Medical University, Fuzhou, China | 2Department of Otolaryngology-Head and Neck Surgery, People's Hospital Affiliated of Quanzhou Medical College, Quanzhou, China | 3School of Physical Education, Quanzhou Normal University, Quanzhou, China | 4Department of Otolaryngology-Head and Neck Surgery, Xiamen Medical College Affiliated Haicang Hospital, The Sixth Hospital of Xiamen City, The Haicang Hospital of Xiamen, Xiamen, China | 5Department of Thyroid Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China  \nCorrespondence: Yun-xia Lv ([83394045@qq.com](83394045@qq.com)) | Geng-ming Cai ([cgmkgx@hotmail.com](cgmkgx@hotmail.com))  \nReceived: 17 May 2025 | Revised: 10 November 2025 | Accepted: 17 December 2025  \nKeywords: LA-HNSCC | neoadjuvant therapy | network meta analysis | ORR | OS | PFS | SAEs  \nABSTRACT  \nBackground: Head and neck squamous cell carcinoma (HNSCC), which constitutes approximately 90% of all head and neck cancers, represents a significant global health burden. A concerning trend is the rising incidence, particularly among younger populations, which has been partly attributed to human papillomavirus (HPV) infection. While treatment outcomes are favorable for early-stage disease, approximately 60% of patients are diagnosed with locally advanced HNSCC (LA-HNSCC), for whom prognosis remains suboptimal. Induction chemotherapy, such as the TPF regimen, is often used to reduce tumor burden but is limited by substantial toxicity. Currently, no global consensus exists on the optimal neoadjuvant approach for LA-HNSCC. This network meta-analysis aims to comprehensively compare the efficacy and safety of available neoadjuvant therapies for LAHNSCC, excluding nasopharyngeal carcinoma due to distinct treatment paradigms, in order to inform clinical decision-making. Aim: To compare the efficacy and safety of different neoadjuvant treatment options in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) .  \nMethods and Results: We conducted a comprehensive literature search across four major databases (PubMed, Web of Science [WOS], Embase, and Cochrane Library) from their inception through August 2024. The primary outcome measures included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and serious adverse events (SAEs) . This analysis included 23 studies (19 randomized controlled trials [RCTs] and 4 non-randomized studies [NRS]) involving 4052 patients. Network meta-analysis (NMA) revealed the following findings: Regarding efficacy, hyperthermia + chemotherapy demonstrated superior outcomes in both ORR and OS, followed by immunotherapy + chemotherapy. Hyperthermia + chemotherapy showed significantly better ORR compared to targeted therapy + chemotherapy, TP, PF, T, and single-agent immunotherapy (p \u003C 0.05). Similarly, immunotherapy + chemotherapy outperformed all other therapies except hyperthermia + chemotherapy in ORR (p \u003C 0.05). For OS, both hyperthermia + chemotherapy and TPF were significantly more effective than PF and TP (p \u003C 0.05) . In PFS, immunotherapy + chemotherapy showed the best results, followed by targeted therapy + chemotherapy, with immunotherapy + chemotherapy being significantly superior to PF (p \u003C 0.05) . Regarding safety, hyperthermia + chemotherapy showed the poorest safety profile, followed by TPF. Specifically, T and TP demonstrated significantly better safety than hyperthermia + Chemotherapyy (p \u003C 0.05) .  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited","cbCair40G92QAFTt","https://ap.wps.com/l/cbCair40G92QAFTt","pdf",8795174,1,24,"English","en",105,"# Abstract\n## Background\n## Aim\n## Methods and Results\n## Conclusion\n# Introduction","[{\"question\":\"What patient population and cancer type does the study focus on?\",\"answer\":\"The study focuses on locally advanced head and neck squamous cell carcinoma (LA-HNSCC), excluding nasopharyngeal carcinoma due to distinct treatment paradigms.\"},{\"question\":\"Which outcomes were used to assess efficacy and safety?\",\"answer\":\"Efficacy was evaluated with objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), while safety was assessed using serious adverse events (SAEs).\"},{\"question\":\"How did hyperthermia plus chemotherapy compare with other regimens?\",\"answer\":\"Hyperthermia plus chemotherapy demonstrated superior ORR and OS compared with several alternatives, but it showed the poorest safety profile among the compared treatments.\"}]","Efficacy and Safety of Different Neoadjuvant Treatment Regimens in Locally Advanced Squamous Head and Neck Cancer | PDF",1790124424,60,4,[32,36,41,46],{"page_no":20,"url":33,"width":34,"height":35},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83698c08293cf2cbc8ed4e9ee6020f01.webp",983,1291,{"page_no":37,"url":38,"width":39,"height":40},2,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12b9b57fc11a6e8ff22b0554d3c8e2fe.webp",982,1290,{"page_no":42,"url":43,"width":44,"height":45},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26141fb441995fb29162027d71a51296.webp",981,1289,{"page_no":30,"url":47,"width":48,"height":49},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98f011e628043fb5e462c89105676a39.webp",980,1287,{"code":4,"msg":5,"data":51},[52,57,61,65,69,74,79,82,87,90,94],{"id":20,"doc_module":4,"doc_module_name":53,"category_name":54,"show_sort_weight":55,"slug":56},"Document","Story & Novel",90,"story-novel",{"id":37,"doc_module":4,"doc_module_name":53,"category_name":58,"show_sort_weight":59,"slug":60},"Literature",80,"literature",{"id":30,"doc_module":4,"doc_module_name":53,"category_name":62,"show_sort_weight":63,"slug":64},"Exam",70,"exam",{"id":66,"doc_module":4,"doc_module_name":53,"category_name":67,"show_sort_weight":29,"slug":68},5,"Comic","comic",{"id":70,"doc_module":4,"doc_module_name":53,"category_name":71,"show_sort_weight":72,"slug":73},6,"Technology",50,"technology",{"id":75,"doc_module":4,"doc_module_name":53,"category_name":76,"show_sort_weight":77,"slug":78},7,"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":53,"category_name":12,"show_sort_weight":80,"slug":81},30,"research-report",{"id":83,"doc_module":4,"doc_module_name":53,"category_name":84,"show_sort_weight":85,"slug":86},9,"Religion & Spirituality",20,"religion-spirituality",{"id":85,"doc_module":4,"doc_module_name":53,"category_name":88,"show_sort_weight":85,"slug":89},"World Cup","world-cup",{"id":91,"doc_module":4,"doc_module_name":53,"category_name":92,"show_sort_weight":91,"slug":93},10,"Lifestyle","lifestyle",{"id":95,"doc_module":4,"doc_module_name":53,"category_name":96,"show_sort_weight":66,"slug":97},19,"General","general",{"code":4,"msg":99,"data":100},"ok",{"site_id":24,"language":23,"slug":101,"title":13,"keywords":102,"description":14,"schema_data":103,"social_meta":156,"head_meta":158,"extra_data":160,"updated_unix":161},"efficacy-and-safety-of-different-neoadjuvant-treatment-regimens-in-locally-advanced-squamous-head-and-neck-cancer","",{"@graph":104,"@context":155},[105,118,138],{"@type":106,"itemListElement":107},"BreadcrumbList",[108,112,114,116],{"item":109,"name":110,"@type":111,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":113,"name":53,"@type":111,"position":37},"https://docshare.wps.com/document/",{"item":115,"name":12,"@type":111,"position":42},"https://docshare.wps.com/document/research-report/",{"item":117,"name":13,"@type":111,"position":30},"https://docshare.wps.com/document/efficacy-and-safety-of-different-neoadjuvant-treatment-regimens-in-locally-advanced-squamous-head-and-neck-cancer/356285/",{"url":117,"name":13,"@type":119,"image":120,"author":125,"headline":13,"publisher":127,"fileFormat":130,"inLanguage":23,"description":14,"dateModified":131,"datePublished":132,"encodingFormat":130,"isAccessibleForFree":133,"interactionStatistic":134},"DigitalDocument",{"url":121,"@type":122,"width":123,"height":124},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-different-neoadjuvant-treatment-regimens-in-locally-advanced-squamous-head-and-neck-cancer/356285.png","ImageObject",300,407,{"name":9,"@type":126},"Person",{"url":109,"name":128,"@type":129},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":135,"interactionType":136,"userInteractionCount":11},"InteractionCounter",{"@type":137},"ViewAction",{"@type":139,"mainEntity":140},"FAQPage",[141,147,151],{"name":142,"@type":143,"acceptedAnswer":144},"What patient population and cancer type does the study focus on?","Question",{"text":145,"@type":146},"The study focuses on locally advanced head and neck squamous cell carcinoma (LA-HNSCC), excluding nasopharyngeal carcinoma due to distinct treatment paradigms.","Answer",{"name":148,"@type":143,"acceptedAnswer":149},"Which outcomes were used to assess efficacy and safety?",{"text":150,"@type":146},"Efficacy was evaluated with objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), while safety was assessed using serious adverse events (SAEs).",{"name":152,"@type":143,"acceptedAnswer":153},"How did hyperthermia plus chemotherapy compare with other regimens?",{"text":154,"@type":146},"Hyperthermia plus chemotherapy demonstrated superior ORR and OS compared with several alternatives, but it showed the poorest safety profile among the compared treatments.","https://schema.org",{"og:url":117,"og:type":157,"og:title":13,"og:site_name":128,"og:description":14},"article",{"robots":159,"canonical":117},"index,follow",{"doc_id":7,"site_id":24},1790146810]